TM6SF2 and metabolic dysfunction-associated steatotic liver disease: To confirm the effect of TM6SF2 on fibrosis in NAFLD, CHC and CHB patients, Eslam et al. used a large cohort of Caucasians and found that rs58542926 has more influence on the serum metabolic profile and predisposed hepatic steatosis, rather than acting directly on liver inflammation and fibrosis [25].